Volume matters: the influence of different botulinum toxin-A dilutions for sialorrhea in amyotrophic lateral sclerosis

Muscle Nerve. 2013 Feb;47(2):276-8. doi: 10.1002/mus.23692. Epub 2012 Dec 28.

Abstract

Introduction: We aimed to determine the effect of different botulinum toxin-A (BTX-A) dilutions on the treatment efficacy and side effects for amyotrophic lateral sclerosis (ALS) related sialorrhea.

Methods: Ten patients were enrolled in the study. BTX-A dilution for Group A was 100 U in 1 ml of saline, whereas the dilution for Group B was 100 U in 2 ml of saline. Both groups received 20 U of BTX-A in each parotid gland, and assessments were made by means of the Drooling Impact Scale, items 1 and 3 of the ALS functional rating scale, and visual analog scales for drooling and swallowing function.

Results: Although both groups exhibited a similar improvement in drooling, Group B had a mild but significant deterioration in bulbar function that was not evident in Group A.

Conclusions: These results suggest that BTX-A has a safer profile when reconstituted with 1 ml instead of 2 ml of saline.

MeSH terms

  • Aged
  • Amyotrophic Lateral Sclerosis / complications*
  • Botulinum Toxins, Type A / administration & dosage*
  • Botulinum Toxins, Type A / therapeutic use
  • Female
  • Humans
  • Male
  • Middle Aged
  • Neuromuscular Agents / administration & dosage*
  • Neuromuscular Agents / therapeutic use
  • Sialorrhea / drug therapy*
  • Sialorrhea / etiology
  • Treatment Outcome

Substances

  • Neuromuscular Agents
  • Botulinum Toxins, Type A